RxDoctor Payments Data

Sarah Borge, MD

Family Medicine · Missoula, MTNPI 1417129149

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.2% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $298, more than ten times the $17 reported in 2021.

$777in general payments, 2019–2025

Across 35 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$130
  • Inspire Medical Systems, Inc.$86
  • Amgen$70
  • AstraZeneca$64
  • Exact Sciences$60
  • Vertex$57
  • plus $309 from 11 others

What the payments were for

  • Food & beverage$76398%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$777 in reported general payments places this provider in the 85th percentile of 426 family medicine providers in Montana.

See all family medicine providers in Montana

Medicare billing

Part B allowed, 2024
$97,926
Medicare patients
144
Services billed
1,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$59,017
JardianceEmpagliflozin22$24,795
Spiriva RespimatTiotropium Bromide19$9,586
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,231
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$5,352
SymbicortBudesonide/Formoterol Fumarate13$3,503
Estradiol28$2,702
Atorvastatin Calcium256$2,335
OxycontinOxycodone Hcl14$2,051
Duloxetine Hcl74$2,037
SynthroidLevothyroxine Sodium42$1,883
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$1,811
Levothyroxine Sodium184$1,691
Omeprazole152$1,512
Ventolin HfaAlbuterol Sulfate27$1,502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$36$59,01752 claims
GSKTrelegy Ellipta$57$8,23113 claims
AstraZenecaSymbicort$64$3,50313 claims
AbbVieSynthroid$130$1,88342 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 426 family medicine providers in Montana.

Other family medicine in Missoula

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →